Physician profile
Thomas Lynch
NPI 1659312791
$1,877.09
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $275.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $262.42 | 2019-2020 | |
| Novo Nordisk INC | $204.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $183.68 | 2019-2020 | |
| Amgen INC. | $175.10 | 2019 | |
| Amarin Pharma, INC. | $174.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.80 | 2019 | |
| Merck Sharp & Dohme LLC | $137.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.62 | 2019-2020 | |
| Gilead Sciences, INC. | $113.19 | 2019 | |
| Pfizer INC. | $64.24 | 2019 | |
| Abbvie INC. | $51.44 | 2019 | |
| Lilly USA, LLC | $34.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.26 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $26.06 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.69 | 2019 | |
| Genzyme Corporation | $24.40 | 2019 | |
| Allergan, INC. | $22.94 | 2019 | |
| Daiichi Sankyo INC. | $14.63 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2019 | |
| Assertio Therapeutics, INC. | $11.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.